Successfully bringing digital health technologies (DHTs) to market using robust regulatory strategies
When bringing a DHT to market, digital health developersmust ensureit meets all necessary regulatory requirements to enable patient access and maximize its full potential. A robust regulatory strategy ensures that DHTs are safe, effective, and meet the necessary quality standards and trust of patients, clinicians, and payers.
To help you implement strategies that account for the positive impact of US regulatory engagement on your products’ commercial success and patient access, theseindustry case studiesillustrate how organizations have successfully engaged with the FDA to gain the necessary authorizations to bring their digital health products to market.
Leveraging the case studies
Use these case studies to learn best practices and lessons from organizations who have undergone FDA review processes. Build on their successful interactions, decisions, and approaches so that you can better engage with the FDA and downstream payer decision-makers to convey high reliability and marketability – leading to greater capital investment and payer willingness to provide patient access to DHTs.
Improving access to novel virtual reality (VR) therapies for…
Using the success stories outlined in these industry case studies, we have identified five strategies you can use to navigate theFDA regulatory process. Learn from real-world examples that highlight:
Diversifying commercialization pathways
Addressing unique AI/ML regulatory needs
Moving from product solutions to integrated platforms
Innovators and industry stakeholders across the healthcare system can use DiMe’s Library of Digital Health Regulations to keep up with the latest regulations and guidances applicable to digital health.